Background
==========

In the last two decades, there is growing evidence of prevalence and prognosis of heart failure with normal ejection fraction (HFNEF), also referred to as diastolic heart failure \[[@B1]\]. HFNEF is characterized by symptoms of heart failure, signs of elevated ventricular filling pressures and impaired relaxation in presence of normal systolic function \[[@B2]\]. In 2007, the Heart Failure and Echocardiography Associations of the European Society of Cardiology proposed in a consensus statement a diagnostic flowchart providing a strategy on \"How to diagnose HFNEF\" \[[@B3]\]. The diagnostic strategy is intended for patients suspected of having HFNEF and is based on the positive predictive value of successive examinations. According to this consensus statement, the diagnosis of HFNEF requires a.) symptoms or signs of heart failure, b.) normal or mildly abnormal systolic LV function, and c.) evidence of diastolic dysfunction.

Diagnostic evidence of diastolic dysfunction can be obtained invasively, or - which is probably more accepted in clinical routine - non-invasively by tissue Doppler. A central parameter derived from tissue Doppler is the ratio E/E\' (early diastolic peak filling velocity as derived from transmitral Doppler/early diastolic peak velocity of the mitral annulus as derived from tissue Doppler). When this ratio exceeds 15, the LV filling pressures are elevated, and - in the presence of normal systolic LV function - highly suggestive for the presence of diastolic dysfunction \[[@B4],[@B5]\]. A \"grey zone\" is the E/E\' ratio ranging from 8 to 15 suggestive but nondiagnostic for the presence of diastolic dysfunction. In this case, the consensus statement suggests implementing additional non-invasive investigations, such as left atrial volume measurement, left ventricular mass measurements, combined assessment of transmitral E/A ratio and deceleration time, or the implementation of blood levels of B-type natriuretic peptides \[[@B3]\].

We thought to use this diagnostic flowchart in a population-based cohort of elderly women, in whom the prevalence of diastolic dysfunction and heart failure is believed to be high \[[@B6],[@B7]\]. The purpose was to evaluate the association of dyspnea with the presence of diastolic dysfunction.

Methods
=======

SALIA cohort population
-----------------------

The SALIA cohort (Study on the influence of Air population on Lung function, inflammation and Aging) was initiated as part of the Environmental Health Surveys introduced by the North Rhine Westfalia government between 1985 and 1994. The study population comprised 4874 women aged 55 at the time of entering the study who were living in predefined residential areas. The study areas were chosen from the highly industrialized Ruhr region which represents a range of high-polluted areas and two rural counties in the north-west of the Ruhr region as reference areas \[[@B8],[@B9]\]. In a follow-up of SALIA cohort from April 2007 to November 2008, 708 women from the Ruhr region cities Duisburg, Dortmund, Essen and Gelsenkirchen and the rural county Borken who survived and agreed in 2006 to participate in a follow-up were invited in a randomised manner and, at least 402 women participated. The protocol of the study was approved by the Medical Ethic Committee of the Ruhr University Bochum. All participants gave informed written consent.

Cardiovascular study cohort
---------------------------

A cross-sectional cardiovascular examination was realized in 344 of 402 participants (86%). The examination consisted of medical history, physical examination, measurement of B-type natriuretic peptide, electrocardiography, and echocardiography.

Exclusion criteria for further analysis were a.) previous heart surgery and/or PCI (n = 5), b.) severe heart valve disease (n = 6), c.) typical angina pectoris ≥ II CCS (n = 3), d.) previous or actual atrial fibrillation or flutter (n = 8), e.) permanent pacemaker stimulation (n = 3), and f.) poor image quality in the echocardiographic examination (n = 10). Nine participants were excluded with a LV EF ≤ 50% and/or LVEDVI ≥ 97 mL/m^2^; further 9 participants were excluded with pulmonary diseases requiring a specific therapy. These latter exclusion criteria were chosen to focus on participants with a normal left ventricular systolic function and normal left ventricular enddiastolic diameter, and to exclude those participants with a significant pulmonary disease. Thus, a total of 291 participants formed the final study group.

Medical history, quality of life and physical examination
---------------------------------------------------------

In a structured interview each participant was asked for detailed medical history, particularly for cardiovascular risk factors, cardiovascular diseases and medication. The Minnesota living with heart failure questionnaire (MLHFQ) was used to assess quality of life \[[@B10]\]. Summation of the responses yielded the total MLHFQ score for each patient. The test ranges between 0 and 110, whereas higher score indicates a poorer quality of life.

Dyspnea was assessed by combining results of the standardized questionnaire and an interview. Participants were asked to asses their degree of functional impairment due to dyspnea and level of activity. With this, dyspnea was categorized according to the New York Heart Association classification.

Physical examination comprised measurements of blood pressure, height, and weight. Arterial hypertension was diagnosed by medical history, medication and blood pressure measurement (systolic pressure \> 140 mmHg and/or diastolic blood pressure \> 90 mmHg).

Measurement of B-type natriuretic peptide and electrocardiography
-----------------------------------------------------------------

Plasma B-type (brain) natriuretic peptide levels (BNP) were measured at the same day as electrocardiography and echocardiography. The blood samples were collected in EDTA-containing tubes. After prompt centrifugation, BNP was measured using a chemiluminescent immunoassay kit (Biosite Triage, San Diego, CA, USA). Electrocardiography was analyzed for arrhythmias.

Echocardiography
----------------

Transthoracic echocardiography was performed according to the guidelines of the American Society of Echocardiography \[[@B11]\] using a digital ultrasound scanner (Vivid 7, General Electrics, Horton, Norway). Data from three cardiac cycles were analyzed. An experienced cardiologist, blinded to the participant\'s clinical data, performed the ultrasound examination and interpreted the results. Left ventricular diameter, posterior wall and septal thickness, aortic root and left atrial diameter were measured by M-Mode from the parasternal views. Left atrial volume was measured by manual tracing of end-systolic endocardial borders using the apical 4-chamber view. Left ventricular myocardial mass was calculated according to the Devereux formula. The Quinones formula was used for measurement of the left ventricular ejection fraction. Values were averaged for each patient. Right atrial and ventricular dimensions were measured in apical 4-chamber and parasternal short-axis views, tricuspid annular plane systolic excursion (TAPSE) was measured by M-mode recordings from the apical 4-chamber view with the cursor placed at the free wall of the tricuspid valve \[[@B12]\]. Peak velocities of early (E) and late (A) diastolic filling and deceleration time were derived from transmitral Doppler profile \[[@B2]\]. Doppler tissue imaging was taken from medial mitral annulus and analyzed for early (E\') and late (A\') diastolic peak velocities \[[@B4]\]. Mitral E/E\' ratio was subsequently calculated.

Inter- and intraobserver correlation for echocardiographic measurements variables reached in our laboratory 0.92 and 0.96, respectively. For assessment of pulmonary artery pressure (PA sys), the systolic pressure gradient between right atrium and ventricle was obtained from the tricuspid regurgitant jet envelope; and the value of 5 mmHg for right atrial pressure was added \[[@B13]\].

Diagnosis of Diastolic Dysfunction
----------------------------------

According to the diagnostic flowchart \[[@B3]\], diastolic dysfunction was assumed when the E/E\' ratio exceeded 15 as derived from tissue Doppler. In case, tissue Doppler yielded an E/E\' ratio ranging from 8 to 15, additional non-invasive parameters had to be fulfilled: left atrial volume index \> 40 ml/m^2^body surface, [or]{.ul} left ventricular mass index \> 122 g/m^2^body surface, [or]{.ul} transmitral E/A ratio \< 0.5 plus deceleration time \> 280 ms, [or]{.ul} blood level of brain natriuretic peptide \> 200 pg/mL.

Statistics
----------

Continuous variables were compared between groups using an unpaired *t*test (for normally distributed variables) or *Mann-Whitney U*test (for non-normally distributed variables). *Chi-square*analysis was used to compare categorical variables. All reported probability values were 2-tailed, and p \< 0.05 was considered statistically significant. Stepwise logistic regression analysis was used to estimate the impact (odds ratio, 95% confidence interval) of the variables history of hypertension, systolic and diastolic blood pressure, heart rate, body mass index (BMI), BNP, the echocardiographic parameters E/E\' ratio, left atrial volume index (LAVI), left ventricular endsystolic/enddiastolic volume indices (LVESVI/LVEDVI), left ventricular mass index (LVMI), right atrial diameter, systolic pulmonary pressure, and TAPSE on the dependent variable dyspnea (SPSS Inc., version 18).

Results
=======

The final study group with 291 participants was homogenous regarding sex (all female), age (range 69 to 79 years), heart rhythm (all in sinus rhythm), and left ventricular systolic function and size (LV EF \> 50%, LVEDVI \< 97 mL/m^2^body surface).

According to the diagnostic flowchart \"How to diagnose HFNEF\", parameters derived from tissue Doppler and laboratory findings (BNP levels) were concordant with the presence of diastolic dysfunction in 122 participants (41.9%). The diagnosis of diastolic dysfunction based in the majority of cases only on two criteria: in about 17% of cases (50/291) on the criterion \"E/E\' ratio \> 15\", and in about 22% of cases (65/291) on the criterion \"15 \> E/E\'\>8 and LVMI \> 122 g/m^2^\" (Figure [1](#F1){ref-type="fig"}).

![**Definitons for diastolic dysfunction**.](1471-2318-11-71-1){#F1}

The participants with diastolic dysfunction had on average a higher body mass index (28.34 ± 4.50 vs. 27.01 ± 4.55 kg/m^2^; p = 0.014), more frequent a history of arterial hypertension (82 vs. 63.9%; p = 0.001) and of hospitalization for congestive heart failure (13.1 vs. 5.3%; p = 0.033), poorer quality of life (9.77 ± 10.52 vs 6.84 ± 8.11 score; p = 0.008), and higher BNP blood levels (86.18 ± 178.92 vs. 51.79 ± 50.4 pg/mL; p = 0.018) as compared to those participants without signs of diastolic dysfunction. The number of participants complaining exertional dyspnea, however, was similar distributed among the subgroups with and without signs of diastolic dysfunction (40.2 vs 40.8%; p = n.s) (Table [1](#T1){ref-type="table"}).

###### 

Comparison of participants with and without diastolic dysfunction

                                   No Diastolic Dysfunction   Diastolic dysfunction   
  -------------------------------- -------------------------- ----------------------- -------
  **Parameter**                    **n = 169**                **n = 122**             **p**
                                                                                      
  Age, years                       74.07 ± 2.53               74.46 ± 2.72            0.210
                                                                                      
  Body mass index, kg/m^2^         27.01 ± 4.55               28.34 ± 4.50            0.014
                                                                                      
  Hypertension, n (%)              108 (63.9)                 100 (82.0)              0.001
                                                                                      
  Diabetes mellitus, n (%)         15 (8.9)                   12 (9.8)                0.941
                                                                                      
  Current smoking, n (%)           8 (4.7)                    1 (1.2)                 0.119
                                                                                      
  Dyslipidemia, n (%)              85 (50.3)                  70 (57.4)               0.282
                                                                                      
  Myocardial infarction, n (%)     8 (4.7)                    11 (9.0)                0.145
                                                                                      
  Hospitalization for CHF, n (%)   9 (5.3)                    16 (13.1)               0.033
                                                                                      
  Stroke, n (%)                    4 (2.4)                    6 (4.9)                 0.394
                                                                                      
  MLHFQ (score)                    6.84 ± 8.11                9.77 ± 10.52            0.008
                                                                                      
  Dyspnea, n (%)                   69 (40.8)                  49 (40.2)               0.994
                                                                                      
  BNP, pg/mL                       51.79 ± 50.4               86.18 ± 178.91          0.018
                                                                                      
  LVEF, %                          68.6 ± 6.8                 68.1 ± 6.0              0.516

Values are mean ± SD if not otherwise noted; CHF = congestive heart failure, MLHFQ = Minnnesota living with heart failure questionnaire, BNP = brain natriuretic peptide, LVEF = left ventricular ejection fraction

Participants with diastolic dysfunction complained about dyspnea in 49 cases (40.2%). It was hypothesized that the participants with dyspnea suffer from a more advanced stage of diastolic dysfunction, i.e. the parameters used to define diastolic dysfunction should be more abnormal as compared to cases without dyspnea. Table [2](#T2){ref-type="table"} compares the \"severity\" for diastolic dysfunction in both subgroups with (n = 49) and without dyspnea (n = 73). The \"diagnostic key parameters\" derived from Doppler echocardiography/tissue Doppler (E/A ratio, DT, E/E\' ratio) revealed on average no significant differences; however the groups differ with respect to BNP, LAVI and LVMI.

###### 

Presence of diastolic dysfunction - comparison of participants with and without dyspnea

                   No Dyspnea     Dyspnea         
  ---------------- -------------- --------------- -------
  BNP, pg/mL       57.1 ± 63.1    164.2 ± 266.6   0.023
  LAVI, ml/kg^2^   21.7 ± 6.4     26.8 ± 9.1      0.001
  LVMI, g/kg^2^    132.2 ± 26.0   141.7 ± 27.8    0.048
  E/A ratio        0.85 ± 0.31    0.95 ± 0.44     0.139
  DT, sec          245.7 ± 58.3   239.0 ± 65.7    0.556
  E/E\' ratio      14.2 ± 3.7     15.3 ± 6.1      0.237

Values are mean ± SD; LAVI = left atrial volume index; LVMI = left ventricular mass index; E = early diastolic filling peak velocity; A = late diastolic filling peak velocity; DT = deceleration time; E/E\' ratio = ratio early diastolic filling velocity/mitral annular peak velocity

A logistic regression model was used to disclose the parameters which predict best dyspnea in participants with diastolic dysfunction. The parameters age, LV ejection fraction and LV volume indices were not added to this analysis, because these parameters were used as pre-selection criteria. The parameters history of hypertension, systolic and diastolic blood pressure, heart rate, the echocardiographic parameters E/E\' ratio and TAPSE did not show a significant association with the variable dyspnea (data not shown). Dyspnea was predicted best by the systolic pulmonary artery pressure, followed by left atrial volume index, BNP, body mass index, and the parameters right atrial diameter and LV mass index (Table [3](#T3){ref-type="table"}).

###### 

Logistic regression analysis, dependent variable dyspnea

  Parameter          Odds Ratio   P      95% Confidence Interval
  ------------------ ------------ ------ -------------------------
  PA sys             1.249        .000   1.113 - 1.400
  LAVI               1.098        .001   1.037 - 1.162
  BNP                1.011        .001   1.004 - 1.109
  BMI                1.151        .002   1.053 - 1.257
  Septal thickness   1.404        .009   1.089 - 1.811
  RAD                1.126        .014   1.025 - 1.238
  LVESDI             1.074        .026   1.009 - 1.145
  LVMI               1.018        .027   1.002 - 1.033

PAsys = systolic pulmonary artery pressure; RAD = right atrial diameter; BMI = body mass index; LVESDI = left ventricular endsystolic diameter index; for other abbreviations see tables 1&2; for parameters LAVI, BMI, septal thickness, RAD, LVESDI and LVMI were measurements available in 122 participants; measurements were available for PAsys and BNP in 50 and 99 participants, respectively

Discussion
==========

Diastolic heart failure is characterized by impaired left ventricular relaxation, increased left ventricular stiffness, increased interstitial deposition of collagen, and modified extracellular matrix proteins \[[@B1],[@B3]\]. It has been estimated that approximately 50% of the heart failure population has a normal left ventricular ejection fraction, and diastolic heart failure may be - at least partially - responsible for heart failure signs and symptoms \[[@B1]\]. Compared with patients with heart failure and reduced LV ejection fraction, individuals with HFNEF are typically older, more likely women, and have a higher likelihood of arterial hypertension \[[@B14]\]. The prognosis of patients with HFNEF appears to be only hardly better than that of individuals with heart failure and impaired LV systolic function \[[@B15],[@B16]\]. While life expectancy increasing, HFNEF may be a growing health problem.

A prerequisite in the diagnosis of HFNEF is the evidence of diastolic dysfunction. The reported prevalence of LV diastolic dysfunction in the general population varies from 11.1 to 34.7% \[[@B6],[@B17]-[@B20]\], and may depend on various factors, in particular the characteristics of the population studied, and the criteria applied to define diastolic dysfunction. In the present cohort of preselected elderly (age range 69-79 years) women with a normal LV ejection fraction and a normal LV geometry, the rate of diastolic dysfunction was as high as 42%. In agreement to previous studies \[[@B6],[@B19],[@B20]\] diastolic dysfunction was associated with a higher body mass index, more frequent with a history of arterial hypertension, a poorer quality of life and higher BNP blood levels as compared to those participants without signs of diastolic dysfunction.

A key element in the diagnosis of HFNEF is the evidence of elevated LV filling. Three ways have been proposed to diagnose raised LV filling pressures: a. invasive measurements, b. unequivocal tissue Doppler measurements, and c. a combination of Doppler echocardiographic parameters and elevated BNP blood levels \[[@B3]\]. Conventional Doppler echocardiographic indices (E/A ratio derived from mitral inflow and pulmonary venous flow patterns) have clear limitations and rarely allow the accurate differentiation between normal from pseudonormal mitral inflow pattern \[[@B1]\]. In the present study we used for diagnosing diastolic dysfunction the flowchart as proposed by the Heart Failure and Echocardiography Associations of the ESC \[[@B3]\]. We focused on the non-invasive arm of the flowchart because of practicability in a population-based survey. This non-invasive arm of the flowchart emphasizes the E/E\' ratio derived from tissue Doppler as one key element of diagnosis of diastolic dysfunction with an E/E\' ratio \> 15 being unequivocal for elevated LV filling pressures. In the present study population, about 17% of cases alone fulfilled this criterion (41% of total subgroup with evidence of diastolic dysfunction). An E/E\' ratio between 8 and 15 appears suggestive but nondiagnostic for diastolic dysfunction, and the flowchart demands further measurements. In the present study we used some but not all criteria proposed by the flowchart: we ignored the criterion \"presence of atrial fibrillation\", because sinus rhythm was an inclusion criterion, as well as the criterion \"difference between duration of reverse pulmonary vein atrial systole flow and duration of mitral valve atrial flow \> 30 ms\", because the pulmonary vein flow pattern was not routinely assessed in our study population. The combined criterion \"15\>E/E\'\>8 and left ventricular mass index \> 122 g/m^2^(for women)\" was positive in our study cohort in 22.3% of cases (53% of total subgroup with evidence of diastolic dysfunction). Taken together, the diagnosis of diastolic dysfunction based in our study population in 94% of cases on two criteria only.

The flowchart allows an alternative pathway to diagnose diastolic dysfunction: the use of the biomarkers brain natriuretic peptide (BNP) or NT-proBNP in first line, in combination with an E/E\' ratio \> 8. In our study population, 7.6% of participants fulfilled this criterion (data not shown). This number is in sharp contrast to the above mentioned cases with diastolic dysfunction diagnosed by tissue Doppler indices in first line (42%).

Somewhat unexpected, the diagnosis of diastolic dysfunction (using tissue Doppler in first line for diagnosis) showed only a poor association with the symptom \"dyspnea\". In fact, approximately 40% of elderly women in the present study cohort complained dyspnea: this symptom, however, was similar distributed among the subgroups with and without signs of diastolic dysfunction. The \"key parameters\" for the diagnosis of diastolic dysfunction (E/A ratio and deceleration time; E/E\' ratio) did not further discriminate those women with diastolic dysfunction and dyspnea. Additional echocardiographic parameters such as the systolic pulmonary pressure, left atrial volume index, right atrial diameter, and left ventricular mass index were more helpful to characterize participants with dyspnea. This observation suggests that the demonstration of elevated LV filling pattern by tissue Doppler alone may be not sufficient to \"explain\" the symptom dyspnea in elderly patients, and other factors have to be taken into consideration. Several causes of dyspnea in elderly have been described \[[@B21]\]. Shortness of breath may be associated with older age, poor perceived health, anxiety and depressive symptoms, impaired daily functioning, lower happiness or muscular disabilities. Our data does not allow discriminating between two possibilities: a. the additional factors may be related to a more advanced stage of diastolic dysfunction with secondary structural and hemodynamic changes, b. the additional factors are the result of co-morbidities such as left ventricular hypertrophy or pulmonary arterial hypertension. Since the magnitude of the E/E\' ratio did not correlate with the symptom dyspnea in women classified for diastolic dysfunction, our data favors the latter suggestion.

As a limiting factor we have to consider, that we can not thoroughly generalize our data to the community because of the study exclusion criteria. However, we wanted to analyze the interplay between diastolic function and dyspnea without apparent underlying diseases.

Conclusion
==========

In summary, our population-based cross-sectional study in elder women confirms a high percentage of participants with signs of diastolic dysfunction, as assessed by the actual diagnostic guidelines of the ESC. According to the guidelines, the diagnosis of diastolic dysfunction based in the majority of cases on two criteria (E/E\' ratio \> 15, 15\>E/E\'\>8 and LVMI \> 122 g/m^2^). The demonstration of diastolic dysfunction showed only a poor association with the symptom dyspnea. Additional structural or hemodynamic changes are necessary to \"explain\" the symptom dyspnea in this cohort of elderly women. It is unclear whether these additional factors are secondary to a more advanced stage of diastolic dysfunction, or are related to cardiovascular co-morbidities, or both.
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